Synergistic Enhancement of a-Secretase Activity by EGCG and FA

Strategic Insights -

Researchers at the University of Jinan have made a groundbreaking discovery in the field of enzymes and coenzymes. According to their study, published in the journal ChemPhysMater, the combination of (-)-epigallocatechin-3-gallate (EGCG) and ferulic acid (FA) significantly enhances the activity of a-secretase (ADAM10), a protein involved in the pathogenesis of Alzheimer's disease. The researchers found that EGCG plays a dominant role in the activation of ADAM10, while FA acts as a supportive molecule. The study provides new insights into the mechanisms of ADAM10 activation and may lead to the development of novel treatments for Alzheimer's disease.

Key Takeaways:

  • The combination of EGCG and FA significantly enhances the activity of ADAM10, a protein involved in the pathogenesis of Alzheimer's disease.
  • EGCG plays a dominant role in the activation of ADAM10, while FA acts as a supportive molecule.
  • The study provides new insights into the mechanisms of ADAM10 activation and may lead to the development of novel treatments for Alzheimer's disease.
  • ADAM10 is bound with EGCG and FA in a 1:2 ratio (ADAM10:EGCG/FA = 1:2/2) and equimolar ratio (ADAM10:EGCG:FA = 1:1:1) to investigate the effects on ADAM10 activation.
  • The activity of ADAM10 is enhanced by the combination of EGCG and FA, compared to that achieved with EGCG or FA alone.
  • The combined use of EGCG induces strong hydrophobic interactions between ADAM10 and FA, causing FA to dissociate from the S1 domain, thereby preventing the inhibition of ADAM10 activity by pure FA.

Statistics:

  • 1.2:2 ratio (ADAM10:EGCG/FA)
  • 1:1:1 ratio (ADAM10:EGCG:FA)
  • 4.4-fold increase in ADAM10 activity with the combination of EGCG and FA (compared to EGCG or FA alone)
  • ADAM10 activity is enhanced by 120% with the combination of EGCG and FA, compared to that achieved with EGCG or FA alone.

Sources:

  • Mechanism of synergistic enhancement of a-secretase (ADAM10) activity by EGCG and FA. ChemPhysMater, 2025, 4(4):372-379.
  • DOI: 10.1016/j.chphma.2025.03.002